melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The positive expression of HER4 was correlated with the prognosis of SNMMM patients (P<0.05).
|
29309357 |
2018 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we want to share our experience regarding major problems associated with FFPE DNA used for PCR-based sequencing as illustrated by the mutational analysis of ERBB4 in melanoma.
|
28314930 |
2017 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
At the same time, high throughput sequencing studies of melanoma unraveled a series of new treatment candidates for future treatment approaches such as ERBB4, GRIN2A, GRM3, and RAC1.
|
25654738 |
2015 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results further emphasize the role of HER4 as an important oncogene in malignant melanoma and point to HER4 as a possible drug target in this disease.
|
24366194 |
2014 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This sequencing technique has successfully been applied within a clinical trial selecting patients with ERBB4-mutant melanoma for lapatinib treatment.
|
24258993 |
2014 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Malignant transformation of melanomas is accompanied by loss of KIT and acquisition of EPO-R and ErbB4, both of which are co-expressed with NGF-R and PD-1 in distinct subfractions of melanoma cells.
|
24489649 |
2014 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in melanoma cell lines correlated with their sensitivity to corresponding small molecule inhibitors, confirming, for example, lapatinib sensitivity in ERBB4 mutant lines and identifying a novel activating mutation of BRAF.
|
24628946 |
2014 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that ERBB4 mutations may play a limited role in melanomas in China; therefore, targeting the ERBB4 mutation in melanoma patients from southern China may not be a promising strategy.
|
23237222 |
2013 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Ligand-mediated activation of ErbB3 and ErbB4 is implicated in the pathogenesis of several human malignancies including cancer of the ovary and melanoma.
|
22856597 |
2012 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Gaining further understanding into the oncogenic mechanism of Erbb4 may not only help in the development of targeted therapy in melanoma patients but might accelerate the acceptance of a novel taxonomy of cancer which is based on the genomic perturbations in cancer genes and cancer gene families and their response to targeted agents.
|
20404484 |
2010 |
melanoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib.
|
19718025 |
2009 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found ERBB4 mutations in 19% of individuals with melanoma and found mutations in two other kinases (FLT1 and PTK2B) in 10% of individuals with melanomas.
|
19718025 |
2009 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
|
19800573 |
2009 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib.
|
19718025 |
2009 |
melanoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|